



Article

Synergistic Cytokine Production by ATP and PGE₂ via P2X₄ and EP₃ Receptors in Mouse Bone-Marrow-Derived Mast Cells

Kosuke Obayashi¹, Kazuki Yoshida¹ , Masa-aki Ito¹, Tetsuya Mori², Kimiko Yamamoto³, Toshiyashu Imai⁴ and Isao Matsuoka^{1,*} 

- ¹ Laboratory of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki 370-0033, Gunma, Japan; 0821024@takasaki-u.ac.jp (K.O.); yoshida-k@takasaki-u.ac.jp (K.Y.); mito@takasaki-u.ac.jp (M.-a.I.)
- ² Laboratory of Allergy and Immunology, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki 370-0033, Gunma, Japan; tmori@takasaki-u.ac.jp
- ³ Department of Biomedical Engineering, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan; kyamamoto@m.u-tokyo.ac.jp
- ⁴ Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato 341-0005, Saitama, Japan; t-imai@chemiphar.co.jp
- * Correspondence: isao@takasaki-u.ac.jp; Tel.: +81-27-352-1180

Abstract: ATP is an important intercellular messenger in the extracellular space. In mast cells (MCs), ATP stimulates the ionotropic P2X₄ receptor (P2X₄R), resulting in enhanced degranulation and exacerbation of acute allergic reactions. In this study, we investigate whether ATP regulates inflammatory cytokine production in MCs. Gene expression was analyzed by quantitative RT-PCR, and cytokine production was measured using ELISA. The stimulation of mouse bone-marrow-derived MCs (BMMCs) with ATP alone had little effect on cytokine secretion. However, the co-stimulation with prostaglandin (PG) E₂ resulted in a marked increase in the secretion of various cytokines, such as tumor necrosis factor- α , interleukin (IL)-6, and IL-13, accompanied by an increase in their mRNA levels. The effects of ATP were inhibited by P2X₄R antagonists and diminished in BMMCs derived from P2X₄R-deficient mice, suggesting that P2X₄R mediated the reaction. The effects of PGE₂ were mimicked by an EP₃ receptor (EP₃R) agonist and blocked by an EP₃R antagonist. The synergistic cytokine mRNA elevations induced by ATP and PGE₂ were blocked by nuclear factor- κ B and Ca²⁺-calcineurin signaling inhibitors. Altogether, these results suggest that combining P2X₄R and EP₃R signaling enhances acute degranulation and the subsequent cytokine secretion, exacerbating allergic inflammation.

Keywords: ATP; bone-marrow-derived mast cells; prostaglandin E₂; P2X₄ receptor; EP₃ receptor



Citation: Obayashi, K.; Yoshida, K.; Ito, M.-a.; Mori, T.; Yamamoto, K.; Imai, T.; Matsuoka, I. Synergistic Cytokine Production by ATP and PGE₂ via P2X₄ and EP₃ Receptors in Mouse Bone-Marrow-Derived Mast Cells. *Cells* **2022**, *11*, 616. <https://doi.org/10.3390/cells11040616>

Academic Editor: Yoshimichi Okayama

Received: 28 December 2021

Accepted: 8 February 2022

Published: 10 February 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Adenosine triphosphate (ATP), an important intracellular energy source constantly supplied by cell metabolism under cellular respiration, is present in high concentrations in the cytosol. However, cells release ATP into the extracellular space as an intercellular mediator to regulate various physiological functions [1]. Extracellular ATP accumulation is recognized by various receptors called P2 receptors. Seven subtypes of ionotropic P2X receptors (P2X₁-7) recognize ATP exclusively and open non-selective cation channels [2]. In contrast, eight subtypes of G protein-conjugated P2Y receptors have been identified in humans, including P2Y₁, Y₂, Y₄, Y₆, and Y₁₁₋₁₄ receptors, and the ligands are not only ATP but also ADP and uridine nucleotides, such as UTP, UDP, and UDP-glucose [3]. Receptor activation is transmitted into cells by the G protein-dependent signaling [3]. In addition, extracellular ATP is rapidly dephosphorylated by various extracellular ATP-degrading enzymes to adenosine, acting as an agonist to another set of P1 adenosine receptors, such as Gi-coupled A₁ and A₃ receptors, and Gs-coupled A_{2A} and A_{2B} receptors [4]. Thus, ATP

is involved in regulating physiological functions as a spatially and temporally diverse intercellular transmitter.

Initially, ATP was focused as a transmitter of non-cholinergic and non-adrenergic neurotransmission in the regulation of the contraction of smooth muscle organs, such as the intestine [5], bladder [6], and seminal vesicle [7]. However, tissue damage or mechanical stimulation causes a large amount of ATP release as a danger or find-me signal [8], facilitating the accumulation of evidence that ATP plays an important role in regulating immune cells. For example, ATP and UTP released from apoptotic cells stimulate P2Y and adenosine receptors on neutrophils [9], macrophages [10], and lymphocytes [11] to promote migration to the affected area. In macrophages, the stimulation of P2X7 receptors activates the inflammasome, promoting IL-1 β processing and inducing IL-1 β release [12]. Activating P2X4 receptors (P2X4R) in microglia plays an essential role in inducing neuropathic pain [13].

Mast cells (MCs) express various P1 and P2 purinergic receptors, and important information about the role of purinergic signaling in MC function has been reported [14]. For example, the stimulation of MCs with high concentrations of ATP induces direct degranulation via P2X7 receptors involved in the pathophysiology of inflammatory bowel disease [15] and skin hypersensitivity [16]. In addition, adenosine promotes antigen-stimulated degranulation via the A₃ receptor [17]. G protein-coupled P2Y receptors are also abundantly expressed in MCs; however, their effects have been reported only for promoting antigen-induced degranulation via the stimulation of P2Y₁₃ and P2Y₁₄ receptors in model cell lines [18,19]. Recently, we reported that ATP promotes antigen-stimulated degranulation via ionotropic P2X4R using mouse bone-marrow-derived MCs (BMMCs) [20]. Furthermore, the P2X4R stimulating effect increased the antigen-independent degranulation reaction [21]. Co-stimulation with the EP₃ receptor (EP₃R) of prostaglandin (PG) E₂ coupled to the G_i protein and the A₃ receptor of adenosine induces a remarkable degranulation reaction. Such enhancement of antigen-dependent and antigen-independent degranulation reactions affected the degree of allergic reaction *in vivo* [20]. Since the magnitude of the degranulation reaction is related to the severity of the immediate allergic reaction, an increase in the P2X4R-mediated degranulation reaction is considered important for understanding allergic reactions.

MCs induce an immediate allergic reaction by releasing granule contents, such as histamine, serotonin, and various proteases, and produce various chemokines and cytokines as a delayed reaction [22]. Compared to the regulatory mechanism of the degranulation reaction, the purinergic regulation of cytokine production in MCs remains unexamined. In this study, we investigate whether extracellular ATP affects the production of cytokines by antigen and non-antigen stimulation using BMMCs.

2. Materials and Methods

2.1. Materials

ATP, α,β -methylene ATP ($\alpha\beta$ meATP), ADP, UTP, PGE₂, dexamethasone, 2,4-dinitrophenyl human serum albumin (DNP-HSA), anti-DNP IgE (clone SPE-7), cyclosporine and the GenElute Mammalian Total RNA miniprep kit were obtained from Sigma-Aldrich (Tokyo, Japan). 1,2-Bis (2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis acetoxymethyl ester (BAPTA-AM) was obtained from Abcam (Cambridge, UK). Allophycocyanin-conjugated rat anti-mouse c-Kit antibodies (clone 2B8) were obtained from BD Pharmingen (Tokyo, Japan). Phycoerythrin-conjugated mouse anti-mouse Fc ϵ RI α antibodies (clone MAR-1) were obtained from eBioscience (San Diego, CA, USA). Recombinant mouse interleukin (IL)-3 and recombinant mouse SCF were obtained from Peprotech (London, UK). SB203580, wortmannin and AH6809 were obtained from Cayman Chemical (Ann Arbor, MI, USA). InSolution NF- κ B activation inhibitor was obtained from Calbiochem (San Diego, CA, USA). U0126, anti-extracellular signal-regulated kinase (ERK)1/2, anti-phospho-ERK1/2, anti-Akt, anti-phospho-Akt (Thr308), anti-NF- κ B p65 and anti-phospho-NF- κ B p65 (Ser536) antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA). Anti-P2X4

antibody was obtained from Alomone Labs (Jerusalem, Israel). Mouse IL-1 β , IL-6, IL-13, and tumor necrosis factor (TNF)- α enzyme-linked immunosorbent assay (ELISA) kits were obtained from Thermo Fisher Scientific (Tokyo, Japan). ONO-DI-004 (EP₁ agonist), ONO-AE1-259-01 (EP₂ agonist), ONO-AE-248 (EP₃ agonist), ONO-AE1-329 (EP₄ agonist), ONO-8713 (EP₁ antagonist), ONO-AE3-208 (EP₃ antagonist), and ONO-AE3-240 (EP₄ antagonist) were obtained from ONO Pharmaceuticals Co., Ltd. (Osaka, Japan). NP-1815-PX (P2X₄ antagonist) was provided by Nippon Chemiphar Co., Ltd. (Tokyo, Japan). All other chemicals were of reagent grade or the highest quality available.

2.2. Animals

P2X₄R-deficient (*P2rx4*^{-/-}) mice were generated by Dr. Yamamoto (University of Tokyo), as described previously [23]. C57BL/6 mice were purchased from SLC Japan (Hamamatsu, Japan). All mice were maintained in the animal facility of the Takasaki University of Health and Welfare under specific pathogen-free conditions. All experiments were performed per the Animal Research Committee of Takasaki University of Health and Welfare regulations (Approval No. 2033, 1 April 2020).

2.3. Cell Culture

BMMCs were prepared from the bone marrow of C57BL/6 mice, as described previously [24]. Briefly, bone marrow cells were collected from the femur and cultured in RPMI 1640 growth medium containing 10% fetal bovine serum, 100 units/mL penicillin, 100 μ g/mL streptomycin, and 10 ng/mL mouse IL-3. After 2 weeks, recombinant SCF (10 ng/mL) was added to the growth medium and cultured for 2–3 weeks. The culture medium was changed twice per week. After these treatments, almost all (> 95%) cells displayed an MC phenotype, as indicated by CD117 (c-Kit), and Fc ϵ RI expression measured using a FACSCant II flow cytometer (BD Biosciences, Tokyo, Japan).

2.4. Measurement of Cytokine Secretion

BMMCs were sensitized with 50 ng/mL anti-DNP IgE overnight in RPMI 1640 growth medium. Cells were washed twice with RPMI medium containing 0.1% bovine serum albumin and then stimulated under various conditions for different periods at 37 °C. The reactions were terminated by centrifugation, and the supernatant and cell pellets were subjected to cytokine measurement using ELISA and RNA extraction, respectively.

2.5. Quantitative RT-PCR

Total RNA was isolated using the GenElute Mammalian Total RNA miniprep kit. First-strand cDNA was synthesized using Moloney murine leukemia virus reverse transcriptase with a 6-mer random primer. Quantitative RT-PCR was performed using an SYBR green kit (Takara bio, Tokyo Japan), as described previously [25].

2.6. Western Blotting

Cells were collected, washed twice with Krebs-Ringer-HEPES buffer (130 mM NaCl, 4.7 mM KCl, 4.0 mM NaHCO₃, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 1.8 mM CaCl₂, and 11.5 mM glucose and 10 mM HEPES (pH 7.4)), and then stimulated under various conditions at 37 °C. The reactions were terminated by adding 4x Laemmli sample buffer. The lysate was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P polyvinylidene fluoride membranes. The membranes were blocked with 5% non-fat milk for 1 h at room temperature and exposed to primary antibodies overnight at 4 °C and then to secondary antibodies for 2 h at room temperature. The antibodies were diluted as follows: anti-phospho-ERK1/2 (1:1000), anti-ERK1/2 (1:1000), anti-phospho-Akt (1:1000), anti-Akt (1:1000), anti-phospho-NF- κ B p65 (1:1000), anti-NF- κ B p65 (1:1000), anti-P2X₄ (1:2000), and horseradish peroxidase (HRP)-linked anti-rabbit IgG (1:10,000). Immunoreactive proteins were detected by enhanced chemiluminescence (GE Healthcare Bio-sciences, Tokyo, Japan) using Image Reader LAS-

3000 (FUJIFILM, Tokyo, Japan). The density of bands was quantified using Multi Gauge version 3.0, and the fold change in phosphorylation was calculated from the amount of phosphoprotein relative to total proteins as a loading index.

2.7. Statistics

All experiments were repeated at least three times, yielding similar results. Data represent the mean \pm standard error of the mean (SEM). Statistical analyses were performed using Student's *t*-test for two-sample comparisons and one-way analysis of variance (ANOVA) with Dunnett's two-tailed test for multiple comparisons. Statistical significance was set at *p*-value < 0.05.

3. Results

3.1. Effects of ATP Combined with PGE₂ and Ag on Cytokine mRNA Expression and Secretion in BMMCs

First, we examined the effects of ATP on PGE₂ or antigen DNP-HSA-induced mRNA expression of inflammatory cytokines, including IL-1 β , IL-6, IL-13, and TNF- α , in BMMCs by quantitative RT-PCR. The BMMCs used in this study hardly expressed the inflammatory cytokine mRNA in the unstimulated condition. However, the co-stimulation of ATP (100 μ M) with PGE₂ (1 μ M) and low doses of antigen DNP-HSA (10 ng/mL) markedly increased cytokine mRNA expression (Figure 1). The increased levels were comparable to the expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a house-keeping gene used as an internal standard. Next, we examined whether the change in mRNA reflected cytokine secretion. The stimulation of the BMMCs for 3 h with ATP alone had little effect on the production of IL-6, IL-13, and TNF- α ; however, co-stimulation with antigen or PGE₂ resulted in a pronounced increase in cytokine secretion. Both the rate and absolute value of the increase were more pronounced when co-stimulated with PGE₂ than with antigen (Figure 2). In contrast, there was almost no IL-1 β secretion, exhibiting increased mRNA levels (data not shown). Therefore, the subsequent experiments dealt with a detailed analysis of the production of IL-6, IL-13, and TNF- α by co-stimulation with ATP and PGE₂.




Figure 1. Effects of ATP on antigen (Ag)- and PGE₂-induced inflammatory cytokine mRNA expressed in the BMMCs. The BMMCs were stimulated with a vehicle (None), DNP-HSA (Ag, 10 ng/mL), or PGE₂ (1 μ M) in the presence or absence of ATP (100 μ M) for 1 h. mRNA expression for (A) IL-1 β , (B) IL-6, (C) IL-13, and (D) TNF- α were examined by quantitative RT-PCR. Data were normalized to GAPDH mRNA levels. Values are shown as mean \pm SEM (*n* = 3). * *p* < 0.05, ** *p* < 0.01.




Figure 2. Effects of ATP on Ag- and PGE₂-induced inflammatory cytokine secretion in the BMMCs. The BMMCs were stimulated with a vehicle (None), DNP-HSA (Ag, 10 ng/mL), or PGE₂ (1 μM) in the presence or absence of ATP (100 μM) for 3 h. Cytokine levels of (A) IL-6, (B) IL-13, and (C) TNF-α were examined by ELISA. Values are shown as mean ± SEM (n = 3). ** p < 0.01.

3.2. Time-Dependent Increase in IL-6 and TNF-α Secretion in Response to ATP, PGE₂, and Their Co-Stimulation

Although an increase in cytokine secretion is accompanied by de novo synthesis in response to stimuli, some cytokines, such as TNF-α, are exited as granule content and increased immediately after stimulation. Therefore, the detailed time-course of changes in cytokine secretion was investigated (Figure 3). ATP stimulation alone did not induce significant cytokine secretion until 24 h. In contrast, PGE₂ stimulated IL-13 and TNFα secretion at 3 h after stimulation and IL-6 secretion at 6 h. When co-stimulated with ATP and PGE₂, a marked increase in IL-6 and IL-13 secretion was observed 3 h after a 1 h time lag. In contrast, TNFα secretion was increased 1 h after co-stimulation with ATP and PGE₂ and reached a peak secretion at 3 h. Based on the above results, the following cytokine secretion was examined 3 h after stimulation, whereas mRNA expression was determined 1 h after stimulation.




Figure 3. Effects of ATP on the time course of PGE₂-induced cytokine secretion in the BMMCs. The BMMCs were stimulated with a vehicle (None), DNP-HSA (10 ng/mL) or PGE₂ (1 μM) in the presence or absence of ATP (100 μM) for 1, 3, 6, 12, and 24 h. Cytokine levels of (A) IL-6, (B) IL-13, and (C) TNF-α were measured by ELISA. Values are shown as mean ± SEM from triplicate determination.

3.3. Effects of Different Concentrations of ATP and PGE₂ on IL-6, IL-13, and TNF-α Secretion

The effects of different concentrations of ATP and PGE₂ on IL-6, IL-13, and TNF-α were examined. ATP alone did not release cytokines up to a concentration of 100 μM; however, the secretion of IL-6, IL-13, and TNF-α increased slightly but constantly at 1 mM. In the presence of PGE₂ (1 μM), ATP increased the secretion of IL-6, IL-13, and TNFα in a concentration-dependent manner from 1 to 100 μM, and the enhancement was decreased at 1 mM. In contrast, PGE₂ elicited IL-6, IL-13, and TNFα secretion at 0.1 to 1 μM even in the

absence of ATP; however, its effects were markedly increased in the presence of 100 μM ATP (Figure 4). Based on these results, 100 μM ATP and 0.1 μM PGE₂ were selected as optimal concentrations for assessing the synergistic secretion of cytokines in the subsequent experiments.




Figure 4. Effects of different concentrations of ATP or PGE₂ on cytokine secretion induced by co-stimulation of ATP and PGE₂ in the BMMCs. The BMMCs were stimulated with different concentrations of ATP (left) or PGE₂ (right) in the presence or absence (alone) of PGE₂ (1 μM) or ATP (100 μM), respectively, for 3 h. (A) IL-6, (B) IL-13, and (C) TNF- α levels in the reaction medium were measured by ELISA. Data are shown as percentage of maximum response obtained with ATP 100 μM + PGE₂ (1 μM). Values are shown as mean \pm SEM ($n = 3$).

3.4. Effects of Different Purinergic Receptor Agonists Combined with PGE₂ on IL-6, IL-13, and TNF- α mRNA Expression

The BMMCs used in our studies expressed multiple P2 receptors stimulated by ATP, including P2X1, P2X4, P2X7, P2Y₁, P2Y₂, and P2Y₁₃ [24]. To examine the receptor subtype involved in ATP enhancement of PGE₂-induced cytokine secretion, the effects of various nucleotide agonists were examined. The agonists used were P2X1 agonist α,β -methylene ATP ($\alpha\beta\text{meATP}$), P2Y₁ and P2Y₁₃ agonist ADP, and P2Y₂ agonist UTP. Among them, ADP enhanced the secretion of IL-6 and IL-13, but was much weaker than ATP. $\alpha\beta\text{meATP}$ and UTP did not increase the effects of PGE₂ (Figure 5).




Figure 5. Effects of different P2 receptor agonists on PGE₂-induced cytokine secretion in the BMMCs. The BMMCs were stimulated with a vehicle (None), ATP (100 μM), α,β -methylene ATP ($\alpha\beta\text{meATP}$, 10 μM), ADP (100 μM), or UTP (100 μM) in the presence (black column) or absence (open column) of PGE₂ (0.1 μM) for 1 h. mRNA expression for (A) IL-6, (B) IL-13, and (C) TNF- α were examined by quantitative RT-PCR. Data were normalized with GAPDH mRNA levels. Values are shown as mean \pm SEM ($n = 3$). * $p < 0.05$, ** $p < 0.01$ vs. PGE₂ alone (none).

3.5. Role of P2X4 Receptor in Enhancing Cytokine mRNA Expression and Secretion by Co-Stimulation of ATP and PGE₂

The responses to P2 agonists shown in Figure 5 were similar to the effects on antigen- and PGE₂-induced MC degranulation via P2X4R. Therefore, the effect of NP-1815-PX, a P2X4R antagonist [26], on cytokine secretion was investigated. NP-1815-PX did not affect cytokine secretion by PGE₂, but significantly suppressed the augmented response induced by ATP

(Figure 6). To further clarify the involvement of P2X4R, we examined the BMMCs prepared from *P2rx4*^{-/-} mice. No increase in cytokine mRNA expression and cytokine secretion was observed in *P2rx4*^{-/-} BMMCs after co-stimulation with ATP and PGE₂ (Figure 7).




Figure 6. Effects of P2X4R antagonist NP-1815-PX on cytokine secretion induced by co-stimulation of ATP and PGE₂ in the BMMCs. The BMMCs were preincubated vehicle (control) and NP-1815-PX (10 μM) for 10 min and then stimulated with vehicle (-) or PGE₂ (0.1 μM) in the presence or absence of ATP (100 μM) for 3 h. (A) IL-6, (B) IL-13, and (C) TNF-α levels in the reaction medium were measured by ELISA. Values are shown as mean ± SEM (n = 3). ** p < 0.01.




Figure 7. Lack of ATP-induced upregulation of PGE₂-induced cytokine production in P2X4R-deficient (*P2rx4*^{-/-}) mice. The BMMCs, prepared from wild-type (WT) and *P2rx4*^{-/-} mice, were stimulated with vehicle (None) or PGE₂ (0.1 μM) in the presence or absence of ATP (100 μM) for (A–C) 1 h or (D–F) 3 h. mRNA expression for (A) IL-6, (B) IL-13, and (C) TNF-α were examined by quantitative RT-PCR. Data were normalized with GAPDH mRNA levels. Values are shown as mean ± SEM (n = 3). ** p < 0.01. The levels of (D) IL-6, (E) IL-13, and (F) TNF-α in the reaction medium were measured by ELISA. Values are shown as mean ± SEM (n = 3). ** p < 0.01.

3.6. Role of EP₃R in Enhancing Cytokine mRNA Expression and Secretion by Co-Stimulation of ATP and PGE₂

We examined the receptors that mediate PGE₂ action. The synergistic increase in cytokine secretion by the co-stimulation of PGE₂ and ATP was reproduced only with the EP₃R agonist ONO-AE-248, and EP₁, EP₂, and EP₄ receptor agonists showed no effect (Figure 8A–C). Conversely, the synergistic increase in cytokine secretion by the co-stimulation of PGE₂ and ATP was suppressed by the EP₃R antagonist ONO-AE3-240, but not by EP₁, EP₂, and EP₄ receptor antagonists (Figure 8D–F). Consistently, the BMMCs predominantly expressed EP₃R mRNA, which was unaffected by P2X4R deficiency (Supplementary Figure S1).




Figure 8. Involvement of EP₃R in PGE₂-induced enhanced cytokine secretion in the presence of ATP in BMMCs. (A–C) The BMMCs were stimulated with PGE₂, ONO-DI-004 (EP₁ agonist), ONO-AE1-259 (EP₂ agonist), ONO-AE-248 (EP₃ agonist), or ONO-AE1-329 (EP₄ agonist) at 0.1 μM with or without ATP (100 μM) for 3 h. The levels of (A) IL-6, (B) IL-13, and (C) TNF-α in the reaction medium were measured by ELISA. Values are shown as mean ± SEM (n = 3). (D–F) The BMMCs were preincubated with a vehicle, ONO-8713 (EP₁ antagonist), AH6809 (EP₂ antagonist), ONO-AE3-240 (EP₃ antagonist), and ONO-AE3-208 (EP₄ antagonist) at 1 μM for 5 min and then stimulated with PGE₂ (0.1 μM) and ATP (100 μM) for 3 h. The levels of (D) IL-6, (E) IL-13, and (F) TNF-α in the reaction medium were measured by ELISA. Values are shown as mean ± SEM (n = 3).

3.7. Effects of ATP and PGE₂ on ERK/Akt/NF-κB Signaling Pathway

The stimulation of the BMMCs with PGE₂ induced the rapid phosphorylation of both ERK1/2 and Akt within 5 min, followed by a decrease to a sustained level at 10 and 20 min. In contrast, ATP had little effect on ERK1/2 and Akt phosphorylation at 5 min, but slightly increased after 10 and 20 min. The co-stimulation of ATP and PGE₂ induced a rapid and sustained increase in ERK1/2 and Akt phosphorylation at 10 and 20 min (Figure 9A,C,D). These co-stimulating effects of ATP and PGE₂ on ERK1/2 and Akt phosphorylation were absent in *P2rx4*^{-/-} BMMCs (Figure 9B–D). Akt is known to activate nuclear factor-κB (NF-κB) [27], a transcription factor for various inflammatory cytokines. ATP or PGE₂ alone only slightly increased the level of phosphorylated NF-κB p65, an activated form of NF-κB. The co-stimulation with ATP and PGE₂ markedly increased the levels of phosphorylated NF-κB (Figure 9A,E). The synergistic phosphorylation of NF-κB by ATP and PGE₂ was absent in *P2rx4*^{-/-} BMMCs (Figure 9B,E). In another set of analysis, we examined the role of P2X4R in the synergistic increase in the phosphorylation of ERK1/2, Akt, and NF-κB by co-stimulation with ATP and PGE₂. P2X4R deficiency abolished the increased phosphorylation of ERK, Akt, and NF-κB (Supplementary Figure S2).




Figure 9. Effects of PGE₂, ATP, and co-stimulation of PGE₂ and ATP on ERK 1/2, Akt and NF-κB phosphorylation in the BMMCs. (A,B) The BMMCs prepared from WT (A) and P2rx4^{-/-} mice (B) were stimulated with PGE₂ (0.1 μM), ATP (100 μM), and PGE₂ and ATP for 5, 10, and 20 min. Cell lysates were subjected to Western blot analysis for phospho-Akt and total Akt (upper), phospho-ERK 1/2 and total-ERK 1/2 (middle), or phospho-NF-κB and total-NF-κB (lower). Blots are representative of three independent experiments. (C) The densitometry value of protein bands of phospho-Akt (C), phospho-ERK 1/2 (D), and phospho-NF-κB (E) are shown as relative intensities, with the results obtained with unstimulated cells (Time 0) designated as 1. Data are shown as mean ± SEM (n = 3). The effect of co-stimulation of PGE₂ and ATP on ERK 1/2, Akt, and NF-κB phosphorylation is significantly different from that of PGE₂ alone. * p < 0.05, ** p < 0.01.

3.8. Effects of Signal Transduction Pathway Inhibitors on the Enhanced Cytokine mRNA Expression by Co-Stimulation with ATP and PGE₂

The effects of various inhibitors against ERK, p38MAPK, phosphatidylinositol 3-kinase (PI3K), calcineurin, and NF-κB were examined. The elevation of cytokine mRNA levels by the co-stimulation of ATP and PGE₂ was attenuated by the ERK inhibitor U0126, PI3K inhibitor wortmannin, NF-κB activation inhibitor NFκBI, calcineurin inhibitor cyclosporine A, intracellular Ca²⁺ chelator BAPTA-AM and the steroidal anti-inflammatory drug dexamethasone. In contrast, the p38MAPK inhibitor SB203580 did not suppress cytokine mRNA expression (Figure 10)




Figure 10. Effects of various inhibitors on the elevation of cytokine mRNA levels induced by the co-stimulation with ATP and PGE₂. (A–C) The BMMCs were preincubated with a vehicle, MEK1/2 inhibitor U0126 (U, 5 μM), p38MAPK inhibitor SB203580 (SB, 10 μM), PI3K inhibitor wortmannin (W, 0.1 μM), NF-κB activation inhibitor (κBI, 1 μM), calcineurin inhibitor cyclosporine A (CyA, 5 μM), intracellular Ca²⁺ chelating agent BAPTA-AM (5 μM) and steroidal anti-inflammatory dexamethasone (Dex, 0.1 μM) for 10 min, followed by stimulation with PGE₂ (0.1 μM) with or without ATP (100 μM) for 1 h. mRNA expression of (A) IL-6, (B) IL-13, and (C) TNF-α was examined by quantitative RT-PCR. Data were normalized with GAPDH mRNA levels and shown as the percentage of the response to PGE₂ and ATP. Values are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01 vs. the response to ATP and PGE₂ and + p < 0.05, ++ p < 0.01 vs. the response to PGE₂.

4. Discussion

In a previous study, we reported that ATP augments IgE-dependent and IgE-independent MC degranulation via P2X4R activation [20,21]. MCs elicit an immediate allergic reaction by releasing chemical mediators stored in the granules; however, in the delayed phase, MCs subsequently secrete diverse inflammatory cytokines and chemokines, causing the migration and activation of other immune cells, resulting in an allergic inflammation [22]. The present study showed that extracellular ATP markedly increased the gene expression and secretion of inflammatory cytokines IL-6 and TNF-α and Th-2 cytokine IL-13 by co-stimulation with antigen and PGE₂. Pharmacological analysis using agonists and antagonists revealed that the effects of ATP and PGE₂ were mediated by P2X4R and EP₃R, respectively, as similar to the effects on degranulation responses [20,21]. The involvement of P2X4R in the ATP-induced effect was confirmed using BMMCs prepared from *P2rx4*^{-/-} mice. Regarding enhancing the degranulation reaction by ATP, the maximum response was not significantly different between the co-stimulation with antigen and with PGE₂ [20,21]. However, the maximum cytokine secretion was much larger in the co-stimulation of ATP with PGE₂ than that with the antigen. FcεRI activation with antigen is triggered by tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) in the FcεRI β subunit. It recruits and activates Lyn kinase resulting in Syk kinase activation, propagating phosphorylation-dependent signals to activate various effector proteins, including phospholipase Cγ [28]. Although FcεRI β subunit is indispensable for FcεRI signaling, the ITAM in the β subunit has an inhibitory regulatory role in MC cytokine production [29], explaining the low cytokine secretion combined with ATP and antigen. In this study, we focused on increased cytokine secretion by co-stimulation with PGE₂ and ATP.

Although various ATP receptors are expressed in MCs, the receptor that mediates the ATP-induced enhancement of cytokine secretion in the presence of PGE₂ was suggested to be the P2X4 receptor, as described above. No increase in cytokine secretion with ATP in the BMMCs prepared from *P2rx4*^{-/-} mice and the failure of αβmeATP and UTP to stimulate cytokine secretion indicates that P2X1 and P2Y₂ receptors expressed abundantly in the BMMCs [24] do not affect cytokine secretion. Among the P2 receptor agonists tested, ADP slightly but significantly enhanced the gene expression of IL-6 and IL-13. Unlike ATP, ADP did not enhance TNF-α expression; hence, it was not the result of P2X4R stimulation with low affinity but of stimulating the Gq-coupled P2Y₁ receptor that recognizes ADP. This result cannot infer that Gq-mediated signals enhance cytokine production, and it is necessary to activate other G proteins, such as G_{12/13}, in addition to Gq [30]. Further studies are needed to validate this hypothesis.

The stimulation of the P2X4 receptor, an ion channel-type receptor, activates the non-selective cation channel, leading to Ca^{2+} influx and depolarization of the membrane potential [31]. It is interesting to understand such a stimulating mechanism affecting the gene expression of inflammatory cytokines. The effect on cytokine production was markedly different among the P2X receptor subtypes expressed in BMMCs. For example, P2X1 receptor stimulation with $\alpha\beta\text{meATP}$ has no effect, whereas P2X7 receptor stimulation with a high ATP concentration (~ 1 mM) alone slightly, but significantly stimulated IL-6, IL-13, and TNF- α secretion. However, unlike the P2X4R-mediated effect, activating the P2X7 receptor did not enhance PGE₂-induced cytokine secretion, but rather inhibited P2X4R-mediated effects. In addition to ion channel function, P2X7 receptor stimulation dilate the channel pore, allowing it to pass with high molecular weight substances, affecting the MC membrane function [32]. The three ionotropic P2X1, P2X4, and P2X7 receptors are functionally expressed in human MCs [33]. The difference in the effects of these P2X receptors on cytokine secretion may be useful in elucidating the unique mechanism of P2X4R action.

Increased cytokine secretion by P2X4R stimulation combined with PGE₂ was accompanied by increased mRNA levels. The time course of cytokine secretion showed an increase in gene expression before the increase in the secretion of all three cytokines examined. Cytokine secretion was not remarkable 1 h after stimulation when a marked mRNA increase was detected. IL-6, IL-13, and TNF- α secretion increased rapidly during 1–3 h after stimulation, and no continuous increase was observed thereafter, suggesting that P2X4R signaling enhances the transcription of inflammatory cytokines. NF- κ B is involved in the transcription of various inflammatory cytokines [22,34]. NF- κ B is present in the cytosol as a complex with I κ B. When I κ B is phosphorylated by IKK, ubiquitination of I κ B progresses its degradation by the proteasome, and the dissociated NF- κ B translocate into the nucleus to stimulate inflammatory cytokine gene expression [35,36]. Among EP₃R downstream signals, ERK1/2 and PI3K-Akt activation participates in NF- κ B signaling pathway [26]. PGE₂ rapidly increased ERK1/2 and Akt phosphorylation, followed by a decrease to low steady levels. In addition, ATP increased phosphorylation of ERK1/2 and Akt in a time-dependent manner, but this action remained in *P2rx4*^{-/-} BMMCs, suggesting effects other than P2X4R. However, our results showed that ATP did not affect PGE₂-induced ERK1/2 and Akt phosphorylation in the early period (5 min), but significantly increased them at later periods (10–20 min). Importantly, this enhancement of PGE₂-induced ERK1/2 and Akt phosphorylation by ATP was absent in *P2rx4*^{-/-} BMMCs. Furthermore, the PI3K inhibitor WMN, the ERK inhibitor U0126, and the NF- κ B inhibitor attenuated the upregulation of inflammatory cytokine expression by ATP in the presence of PGE₂. These results suggest that P2X4R stimulation enhances the ERK1/2 and PI3K/Akt/NF- κ B signaling pathway and increases inflammatory cytokine gene expression. Consistent with this hypothesis, the steroidal anti-inflammatory dexamethasone, which potently inhibits the NF- κ B pathway [37], also inhibited inflammatory cytokine mRNA expression induced by ATP and PGE₂. More direct evidence was observed with the change in phosphorylated NF- κ B p65, a form of activated NF- κ B. Namely, ATP or PGE₂ alone induced only a slight increase in phosphorylated NF- κ B p65, but their combination markedly increased the phosphorylated NF- κ B p65. In addition, this effect was absent in *P2rx4*^{-/-} BMMCs. The phosphorylation of NF- κ B p65 by ATP and PGE₂ was rapidly induced within 5 min and returned to basal levels in 20 min. These changes are consistent with the rapid induction of cytokine mRNAs. This also suggests that sustained elevations of ERK and Akt after 10 min are not responsible for NF- κ B phosphorylation but may support NF- κ B-dependent cytokine gene transcription.

In addition to NF- κ B-dependent signaling, a recent study reported by Jordan et al. [38] demonstrated that Ca^{2+} -calcineurin signaling is involved in cytokine secretion induced by co-stimulation with ATP and IL-33. In this study, we also showed that the intracellular Ca^{2+} chelating agent BAPTA-AM and the calcineurin inhibitor cyclosporine A inhibited inflammatory cytokine mRNA expression induced by ATP and PGE₂. P2X4R-mediated Ca^{2+} influx may stimulate calcineurin-dependent NFAT signaling, resulting in increased

inflammatory cytokine gene transcription. Since P2X1 and P2X7 receptors, which input signals qualitatively similar to P2X4R, did not show interplay with EP₃R signaling, P2X4R may transmit unspecified and unique signals, which is considered an important issue that needs to be addressed.

5. Conclusions

The present study revealed that extracellular ATP enhanced inflammatory cytokine secretion from stimulated MCs via P2X4R activation. This enhancement was more pronounced with co-stimulation with PGE₂ than with antigen. Since both PGE₂ and ATP are commonly accumulated in the inflamed microenvironment, these mediators should affect MC function in various physiological and pathophysiological situations. The cross-talk between P2X4R and EP₃R signals upregulates an acute degranulation response and following inflammatory cytokine secretion, suggesting that these receptors may be potential therapeutic targets for diseases caused by MCs.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/cells11040616/s1>, Figure S1: Expression of mRNAs for EP receptor subtypes in BMDC obtained from wild type and P2X4 receptor deficient mice. Figure S2: Effects of co-stimulation of ATP and PGE₂ on the phosphorylation of ERK1/2, Akt, and NF-κB.

Author Contributions: Conceptualization, K.O., K.Y. (Kazuki Yoshida), M.-a.I. and I.M.; methodology, K.O., K.Y. (Kazuki Yoshida), M.-a.I. and I.M.; formal analysis, K.O.; investigation, K.O., I.M. and T.M.; resources, K.Y. (Kimiko Yamamoto), T.I.; data curation, K.O.; writing—original draft preparation, K.O.; writing—review and editing, I.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Japan Society for the Promotion of Science: Grant-in-Aid for Scientific Research (grant numbers, 18K14925 to K.Y., 19K07328 to I.M., and 20K16010 to M.-a.I.).

Institutional Review Board Statement: The animal study protocol was approved by the Animal Research Committee of Takasaki University of Health and Welfare regulations (Approval No. 2033, 1 April 2020).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the main text.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Burnstock, G. Pathophysiology and Therapeutic Potential of Purinergic Signaling. *Pharmacol. Rev.* **2006**, *58*, 58–86. [[CrossRef](#)]
2. North, R.A.; Surprenant, A. Pharmacology of Cloned P2X Receptors. *Annu. Rev. Pharmacol. Toxicol.* **2000**, *40*, 563–580. [[CrossRef](#)]
3. Jacobson, K.A.; Delicado, E.G.; Gachet, C.; Kennedy, C.; Von Kügelgen, I.; Li, B.; Miras-Portugal, M.T.; Novak, I.; Schöneberg, T.; Perez-Sen, R.; et al. Update of P2Y receptor pharmacology: IUPHAR Review 27. *J. Cereb. Blood Flow Metab.* **2020**, *177*, 2413–2433. [[CrossRef](#)] [[PubMed](#)]
4. Matsuoka, I.; Ohkubo, S. ATP- and adenosine-mediated signaling in the central nervous system: Adenosine receptor activation by ATP through rapid and localized generation of adenosine by ecto-nucleotidases. *J. Pharmacol. Sci.* **2004**, *94*, 95–99. [[CrossRef](#)] [[PubMed](#)]
5. Pinna, C.; Knigh, G.E.; Puglisi, L.; Burnstock, G. Neurogenic and non-neurogenic responses in the urinary bladder of hibernating hamster. *Br. J. Pharmacol.* **1998**, *123*, 1281–1287. [[CrossRef](#)] [[PubMed](#)]
6. Hoyle, C.H.; Knight, G.E.; Burnstock, G. Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli. *J. Cereb. Blood Flow Metab.* **1990**, *99*, 617–621. [[CrossRef](#)] [[PubMed](#)]
7. Nakanish, H.; Takeda, H. The possibility that adenosine triphosphate is an excitatory transmitter in guinea-pig seminal vesicle. *Jpn. J. Pharmacol.* **1972**, *22*, 269–270. [[CrossRef](#)]
8. Elliott, M.; Cheken, F.B.; Trampont, P.C.; Lazarowski, E.R.; Kadl, A.; Walk, S.F.; Park, D.; Woodson, R.I.; Ostankovitch, M.; Sharma, P.; et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nature* **2009**, *461*, 282–286. [[CrossRef](#)]
9. Chen, Y.; Corriden, R.; Inoue, Y.; Yip, L.; Hashiguchi, N.; Zinkernagel, A.; Nizet, V.; Insel, P.A.; Junger, W.G. ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors. *Science* **2006**, *314*, 1792–1795. [[CrossRef](#)] [[PubMed](#)]

10. Kronlage, M.; Song, J.; Sorokin, L.; Isfort, K.; Schwerdtle, T.; Leipziger, J.; Robaye, B.; Conley, P.B.; Kim, H.-C.; Sargin, S.; et al. Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis. *Sci. Signal.* **2010**, *3*, ra55. [[CrossRef](#)]
11. Yip, L.; Woehrlé, T.; Corriden, R.; Hirsh, M.; Chen, Y.; Inoue, Y.; Ferrari, V.; Insel, P.A.; Junger, W.G. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. *FASEB J.* **2009**, *23*, 1685–1693. [[CrossRef](#)]
12. Karmakar, M.; Katsnelson, M.A.; Dubyak, G.R.; Pearlman, E. Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1 β secretion in response to ATP. *Nat. Commun.* **2016**, *7*, 10555. [[CrossRef](#)] [[PubMed](#)]
13. Tsuda, M.; Shigemoto-Mogami, Y.; Koizumi, S.; Mizokoshi, A.; Kohsaka, S.; Salter, M.W.; Inoue, K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. *Nature* **2003**, *424*, 778–783. [[CrossRef](#)]
14. Bulanova, E.; Bulfone-Paus, S. P2 receptor-mediated signaling in mast cell biology. *Purinergic Signal.* **2009**, *6*, 3–17. [[CrossRef](#)] [[PubMed](#)]
15. Kurashima, Y.; Amiya, T.; Nochi, T.; Fujisawa, K.; Haraguchi, T.; Iba, H.; Tsutsui, H.; Sato, S.; Nakajima, S.; Iijima, H.; et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. *Nat. Commun.* **2012**, *3*, 1034. [[CrossRef](#)]
16. Weber, F.C.; Esser, P.; Müller, T.; Ganesan, J.; Pellegatti, P.; Simon, M.M.; Zeiser, R.; Idzko, M.; Jakob, T.; Martin, S.F. Lack of the purinergic receptor P2X7 results in resistance to contact hypersensitivity. *J. Exp. Med.* **2010**, *207*, 2609–2619. [[CrossRef](#)] [[PubMed](#)]
17. Laffargue, M.; Calvez, R.; Finan, P.; Trifilieff, A.; Barbier, M.; Altruda, F.; Hirsch, E.; Wymann, M.P. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. *Immunity* **2002**, *16*, 441–451. [[CrossRef](#)]
18. Gao, Z.-G.; Ding, Y.; Jacobson, K.A. P2Y13 receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells. *Pharmacol. Res.* **2010**, *62*, 500–505. [[CrossRef](#)]
19. Gao, Z.-G.; Wei, Q.; Jayasekara, M.P.S.; Jacobson, K.A. The role of P2Y14 and other P2Y receptors in degranulation of human LAD2 mast cells. *Purinergic Signal.* **2012**, *9*, 31–40. [[CrossRef](#)] [[PubMed](#)]
20. Yoshida, K.; Ito, M.-A.; Sato, N.; Obayashi, K.; Yamamoto, K.; Koizumi, S.; Tanaka, S.; Furuta, K.; Matsuoka, I. Extracellular ATP Augments Antigen-Induced Murine Mast Cell Degranulation and Allergic Responses via P2X4 Receptor Activation. *J. Immunol.* **2020**, *204*, 3077–3085. [[CrossRef](#)]
21. Yoshida, K.; Tajima, M.; Nagano, T.; Obayashi, K.; Ito, M.; Yamamoto, K.; Matsuoka, I. Ito Co-Stimulation of Purinergic P2X4 and Prostanoid EP3 Receptors Triggers Synergistic Degranulation in Murine Mast Cells. *Int. J. Mol. Sci.* **2019**, *20*, 5157. [[CrossRef](#)] [[PubMed](#)]
22. Mukai, K.; Tsai, M.; Saito, H.; Galli, S.J. Mast cells as sources of cytokines, chemokines, and growth factors. *Immunol. Rev.* **2018**, *282*, 121–150. [[CrossRef](#)] [[PubMed](#)]
23. Yamamoto, K.; Sokabe, T.; Matsumoto, T.; Yoshimura, K.; Shibata, M.; Ohura, N.; Fukuda, T.; Sato, T.; Sekine, K.; Kato, S.; et al. Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. *Nat. Med.* **2006**, *12*, 133–137. [[CrossRef](#)] [[PubMed](#)]
24. Yoshida, K.; Ito, M.; Matsuoka, I. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells. *Int. Immunopharmacol.* **2017**, *43*, 99–107. [[CrossRef](#)]
25. Ito, M.; Matsuoka, I. Inhibition of P2Y6 receptor-mediated phospholipase C activation and Ca²⁺ signalling by prostaglandin E2 in J774 murine macrophages. *Eur. J. Pharmacol.* **2015**, *749*, 124–132. [[CrossRef](#)]
26. Matsumura, Y.; Yamashita, T.; Sasaki, A.; Nakata, E.; Kohno, K.; Masuda, T.; Tozaki-Saitoh, H.; Imai, T.; Kuraishi, Y.; Tsuda, M.; et al. A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. *Sci. Rep.* **2016**, *6*, 32461. [[CrossRef](#)]
27. Kane, L.P.; Mollenauer, M.N.; Xu, Z.; Turck, C.W.; Weiss, A. Akt-dependent phosphorylation specifically regulates Cot induction of NF- κ B-dependent transcription. *Mol. Cell Biol.* **2002**, *22*, 5962–5974. [[CrossRef](#)]
28. Gilfillan, A.M.; Rivera, J. The tyrosine kinase network regulating mast cell activation. *Immunol. Rev.* **2009**, *228*, 149–169. [[CrossRef](#)]
29. Furumoto, Y.; Nunomura, S.; Terada, T.; Rivera, J.; Ra, C. The Fc ϵ RI β immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and I κ B kinase phosphorylation and mast cell cytokine production. *J. Biol. Chem.* **2004**, *279*, 49177–49187. [[CrossRef](#)]
30. Ito, M.; Kojima, E.; Yanagihara, Y.; Yoshida, K.; Matsuoka, I. Differential effects of Gq protein-coupled uridine receptor stimulation on IL-8 production in 1321N1 human astrocytoma cells. *Biol. Pharm. Bull.* **2022**, in press.
31. Suurväli, J.; Boudinot, P.; Kanellopoulos, J.; Rützel Boudinot, S. P2X4: A fast and sensitive purinergic receptor. *Biomed. J.* **2017**, *40*, 245–256. [[CrossRef](#)]
32. Di Virgilio, F.; Dal Ben, D.; Sarti, A.C.; Giuliani, A.L.; Falzoni, S. The P2X7 Receptor in Infection and Inflammation. *Immunity* **2017**, *47*, 15–31. [[CrossRef](#)] [[PubMed](#)]
33. Wareham, K.; Vial, C.; Wykes, R.; Bradding, P.; Seward, E. Functional evidence for the expression of P2X1, P2X4 and P2X7 receptors in human lung mast cells. *J. Cereb. Blood Flow Metab.* **2009**, *157*, 1215–1224. [[CrossRef](#)] [[PubMed](#)]
34. Lee, S.A.; Fitzgerald, S.M.; Huang, S.K.; Li, C.; Chi, D.S.; Milhorn, D.M.; Krishnaswamy, G. Molecular regulation of interleukin-13 and monocyte chemoattractant protein-1 expression in human mast cells by interleukin-1 β . *Am. J. Respir. Cell Mol. Biol.* **2004**, *31*, 283–291. [[CrossRef](#)] [[PubMed](#)]
35. Baldwin, A.S., Jr. Series introduction: The transcription factor NF- κ B and human disease. *J. Clin. Invest.* **2001**, *107*, 3–6. [[CrossRef](#)]

36. Karin, M.; Ben-Neriah, Y. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. *Annu. Rev. Immunol.* **2000**, *18*, 621–663. [[CrossRef](#)] [[PubMed](#)]
37. Ray, A.; Prefontaine, K.E. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 752–756. [[CrossRef](#)]
38. Jordan, P.M.; Andreas, N.; Groth, M.; Wegner, P.; Weber, F.; Jager, U.; Kuchler, C.; Werz, O.; Serfling, E.; Kamradt, T.; et al. ATP/IL-33-triggered hyperactivation of mast cells results in an amplified production of pro-inflammatory cyto-kines and eicosanoids. *Immunology* **2021**, *164*, 541–554. [[CrossRef](#)]